Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection
DOI:
https://doi.org/10.31729/jnma.5538Keywords:
COVID-19, immunity, reactivation, reinfectionAbstract
While there is absolutely no evidence to ensure recovered patients are either likely or unlikely to get reinfected. But studies in non-human primates indicate that reinfection of recovered patients is highly unlikely. It is also clear that primary immune responses or induced immunity to severe acute respiratory syndrome coronavirus 2 remain in circulation for several months and at least temporarily confer immunity to protect from reinfection. In addition, negative virus culture analysis of re-positive suggests that positive reverse transcriptase-polymerase chain reactions in recovered patients are more likely to be false-positive, or detection of genetic remnants of virus discharged from lesions of lungs or better sampling at the time of repeat analysis. However, emerging severe acute respiratory syndrome coronavirus 2 variants are likely to be causing the infections observed in some of the recovered patients.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Rupendra Shrestha, Reena Shrestha, Ram Bahadur Khadka, Rabin Gyawali
This work is licensed under a Creative Commons Attribution 4.0 International License.
JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.